NEW YORK, September 29, 2015 /PRNewswire/ --

Equity Research Institute has initiated coverage on the following equities: Geron Corporation (NASDAQ: GERN), VIVUS Inc. (NASDAQ: VVUS), Halozyme Therapeutics Inc. (NASDAQ: HALO), Advaxis Inc. (NASDAQ: ADXS), and Progenics Pharmaceuticals Inc. (NASDAQ: PGNX). Free research report on Geron can be accessed at https://www.erionline.net/GERN.pdf On Monday, September 28, 2015, the NASDAQ Composite ended at 4,543.97, down 3.04%, the Dow Jones Industrial Average declined 1.92%, to finish the day at 16,001.89, and the S&P 500 closed at 1,881.77, down 2.57%. The losses were broad based as all the sectors ended the session in negative. Register for your complimentary reports at the links given below.  

Geron Corp.'s stock declined 5.57%, to close the day at $2.88. The stock recorded a trading volume of 3.46 million shares, much above its three months average volume of 2.81 million shares. Over the last one month and over the past three months, Geron Corp.'s shares have declined 6.49% and 29.58%, respectively. Furthermore, the stock has lost 11.38% since the start of this year. The company's shares are trading 18.73% below their 50-day moving average. Additionally, Geron Corp. has a Relative Strength Index (RSI) of 35.14. Sign up and read the free notes on GERN at:

https://www.erionline.net/GERN.pdf

On Monday, shares in VIVUS Inc. recorded a trading volume of 8.60 million shares, higher than their three months average volume of 2.80 million shares. The stock ended the day 9.62% higher at $1.71. Although, VIVUS Inc.'s stock has surged 54.05% in the last one month, it has plummeted 26.61% in the previous three months and 40.63% on YTD basis. The company is trading above its 50-day moving average by 19.29%. Furthermore, shares of VIVUS Inc. have an RSI of 60.20. The complimentary notes on VVUS can be downloaded in PDF format at:

https://www.erionline.net/VVUS.pdf

Halozyme Therapeutics Inc.'s stock plummeted 9.49%, to close Monday's session at $14.50. The stock recorded a trading volume of 1.97 million shares, above its three months average volume of 1.37 million shares. Over the last one month and the previous three months, Halozyme Therapeutics Inc.'s shares have declined 19.62% and 31.73%, respectively. However, the stock has surged 50.26% since the start of this year. The company is trading 26.95% and 13.78% below its 50-day and 200-day moving averages, respectively. Furthermore, Halozyme Therapeutics Inc.'s stock has an RSI of 29.07. Register for free on Equity Research Institute and access the latest research on HALO at:

https://www.erionline.net/HALO.pdf

Advaxis Inc.'s stock finished Monday's session 11.60% lower at $12.19. A total of 2.77 million shares were traded, which was above its three months average volume of 1.34 million shares. Over the last one month and the previous three months, Advaxis Inc.'s shares have declined 18.57% and 29.37%, respectively. However, the stock has gained 52.18% since the beginning of 2015. The company's shares are trading below their 50-day and 200-day moving averages by 23.40% and 19.87%, respectively. Advaxis Inc.'s stock has an RSI of 35.51. The complete research on ADXS is available for free at:

https://www.erionline.net/ADXS.pdf

On Monday, shares in Progenics Pharmaceuticals Inc. ended the session 8.05% lower at $5.94. The stock reported a trading volume of 1.26 million shares, close to its three months average volume of 1.32 million shares. Shares of the company traded at a PE ratio of 99.00. Progenics Pharmaceuticals Inc.'s shares have declined 24.14% in the last one month, 9.45% in the previous three months and 21.43% on YTD basis. The company is trading 24.12% below its 50-day moving average and 11.76% below its 200-day moving average. Moreover, shares of Progenics Pharmaceuticals Inc. have an RSI of 28.67. Free in-depth research on PGNX is available at:

https://www.erionline.net/PGNX.pdf

--

About Equity Research Institute: 

Equity Research Institute ("ERI") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ERI has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

ERI has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:  

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA(R) charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the Sponsor have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the Sponsor (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.

NO WARRANTY 

ERI, the Author, the Reviewer and the Sponsor (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ERI nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.erionline.net.

RESTRICTIONS 

ERI is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia.

CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.

SOURCE www.erionline.net